Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors

Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

(2013) H. Kamiyama et al.   CLINICAL CANCER RESEARCH

Everolimus for the treatment of pancreatic neuroendocrine tumors

(2012) Georg Feldmann et al.   EXPERT OPINION ON PHARMACOTHERAPY

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma

(2012) Natalie Cook et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Patient-derived tumour xenografts as models for oncology drug development

(2012) John J. Tentler et al.   Nature Reviews Clinical Oncology

Sunitinib

(2011) Emma D. Deeks et al.   BIODRUGS

Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression

(2011) M. Franco et al.   BLOOD

Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies

(2011) T. C. Gangadhar et al.   CLINICAL CANCER RESEARCH

An Algorithm for the Management of Hypertension in the Setting of Vascular Endothelial Growth Factor Signaling Inhibition

(2011) M. Sitki Copur et al.   Clinical Colorectal Cancer

Use of a Mouse Model of Pancreatic Neuroendocrine Tumors to Find Pericyte Biomarkers of Resistance to Anti-angiogenic Therapy

(2011) M. Franco et al.   HORMONE AND METABOLIC RESEARCH

New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects

(2011) G. Aparicio-Gallego et al.   MOLECULAR CANCER THERAPEUTICS

Translational medicine: Cancer lessons from mice to humans

(2011) David Tuveson et al.   NATURE

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

(2011) Y. Jiao et al.   SCIENCE

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

(2010) Jonathan R. Strosberg et al.   CANCER

Pharmacokinetics of sunitinib malate in subjects with hepatic impairment

(2010) Carlo L. Bello et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Evaluation of the Combination 5-Fluorouracil, Dacarbazine, and Epirubicin in Patients With Advanced Well-Differentiated Neuroendocrine Tumors

(2010) Thomas Walter et al.   Clinical Colorectal Cancer

NANETS Treatment Guidelines

(2010) Matthew H. Kulke et al.   PANCREAS

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

(2009) Joshua Ö. Haznedar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

(2009) B. E. Houk et al.   CLINICAL CANCER RESEARCH

Efficacité spectaculaire d’une chimiothérapie par 5-fluoro-uracile et dacarbazine chez un malade atteint de glucagonome métastatique avec insuffisance cardiaque

(2009) L. de Mestier et al.   GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE

Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors

(2009) Marlies H.G. Langenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function

(2009) Reza Khosravan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors

(2009) Barbro Eriksson et al.   NEUROENDOCRINOLOGY

Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449

(2009) Charles M. Rudin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neuroendocrine Tumors of the Pancreas

(2009) F. Ehehalt et al.   ONCOLOGIST

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

Interventional treatment of neuroendocrine liver metastases

(2009) U. Knigge et al.   SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND

Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy

(2008) J. O. Curwen et al.   CLINICAL CANCER RESEARCH

O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors

(2008) M. H. Kulke et al.   CLINICAL CANCER RESEARCH

Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2

(2008) S. Shukla et al.   DRUG METABOLISM AND DISPOSITION

Sex-specific differences in CYP450 isoforms in humans

(2008) Marissa J Scandlyn et al.   Expert Opinion on Drug Metabolism & Toxicology

Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

(2008) Matthew H. Kulke et al.   JOURNAL OF CLINICAL ONCOLOGY